Vol 9, Issue 429
Antiplatelet drugs might inhibit the nexus of platelet activation and amyloid-β aggregation in Alzheimer’s disease.
- Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3–induced outside-in signaling and clusterin release
Alzheimer’s disease patients may benefit from antiplatelet therapy.
- Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues
Structurally redesigned estrogens improve metabolism and vascular repair without activating cell proliferation.
- Dephosphorylation of the adaptor LAT and phospholipase C–γ by SHP-1 inhibits natural killer cell cytotoxicity
Researchers identify targets of a phosphatase that inhibits the activity of natural killer cells.
This week’s articles highlight drug resistance in glioma, HIV-1 immunotherapy, synaptic development, the bacterial starvation response, and negative cooperativity in signaling networks.